Zoetis Inc. (NYSE:ZTS) Q1 2025 Earnings Call Transcript
Operator: Welcome to the First Quarter 2025 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
Zoetis Inc. (ZTS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bristol Gate Capital Partners Peter Simmie | 535,584 | $88,183,829 | +2% | 4.31% |
| 2. | Impax Asset Management Ian Simm | 254,407 | $41,729,390 | +153% | 0.25% |
| 3. | Bailard Inc Thomas Bailard | 65,569 | $10,795,936 | +2% | 0.28% |
| 4. | Heathbridge Capital Management Robert Richards | 61,325 | $10,097,161 | -2% | 4.1% |
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 38,269 | $6,300,991 | +131% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.48 | 2,100 | Director | 7,590 | 2021-02-19 | Filing | |
| $164.89 | 2,900 | Director | 5,490 | 2021-02-19 | Filing | |
| $163.80 | 2,590 | Director | 2,590 | 2021-02-19 | Filing | |
| $74.56 | 10 | Director | 17 | 2018-01-11 | Filing | |
| $50.31 | 7 | Director | 7 | 2016-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $170.00 | 326 | Officer | 15,781 | 2025-03-10 | Filing | |
| $166.14 | 1,210 | Director | 11,245 | 2025-03-11 | Filing | |
| $156.68 | 382 | Officer, Director | 94,194 | 2025-02-19 | Filing | |
| $171.18 | 326 | Officer | 16,107 | 2025-02-11 | Filing | |
| $177.46 | 3,477 | Officer | 3,249 | 2024-11-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 38,482,557 | $6,336,152,940 | 0.13% | |
| 2. | 5,304,166 | $873,330,947 | 0.17% | |
| 3. | 4,408,542 | $725,866,397 | 1.04% | |
| 4. | 2,671,742 | $439,850,558 | 0.49% | |
| 5. | 2,615,019 | $430,562,878 | 3.47% |
News See All
15 Stocks with Buy Ratings that Hedge Funds Love
The U.S. stock market has been in chaos ever since President Trump announced his intent to increase tariffs on the U.S.'s trading partners.
8 Best Pet Stocks to Buy According to Billionaires
The pet industry is expected to continue growing in the coming years, driven by changing consumer preferences and innovative trends.
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
Zoetis (ZTS) Declined in Q4 Despite Posting Excellent Results
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The U.S.
10 Best Weight Loss Drug Stocks to Buy According to Analysts
Most people have tried to include fitness and weight loss into their everyday routines.
What Makes Zoetis (ZTS) a Compelling Opportunity?
Brown Advisors, an investment management company, released its “Brown Advisors Global Leaders Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
Zoetis Inc. (NYSE:ZTS) Q4 2024 Earnings Call Transcript
Operator: Welcome to the Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast for Zoetis.
10 Best Drug Stocks to Buy Now
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for medicines in China.
Zoetis Inc. (ZTS): A Bull Case Theory
We came across a bullish thesis on Zoetis Inc. (ZTS) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.